Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.01
DPLO's Cash-to-Debt is ranked lower than
100% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. DPLO: 0.01 )
Ranked among companies with meaningful Cash-to-Debt only.
DPLO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.11 Max: No Debt
Current: 0.01
0.01
No Debt
Equity-to-Asset 0.43
DPLO's Equity-to-Asset is ranked lower than
78% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. DPLO: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
DPLO' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.37  Med: 0.49 Max: 0.59
Current: 0.43
-0.37
0.59
Debt-to-Equity 0.82
DPLO's Debt-to-Equity is ranked lower than
78% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. DPLO: 0.82 )
Ranked among companies with meaningful Debt-to-Equity only.
DPLO' s Debt-to-Equity Range Over the Past 10 Years
Min: -16.48  Med: 0.23 Max: 3.34
Current: 0.82
-16.48
3.34
Debt-to-EBITDA 5.22
DPLO's Debt-to-EBITDA is ranked lower than
82% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. DPLO: 5.22 )
Ranked among companies with meaningful Debt-to-EBITDA only.
DPLO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.37  Med: 1.58 Max: 27.57
Current: 5.22
-4.37
27.57
Interest Coverage 0.82
DPLO's Interest Coverage is ranked lower than
97% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. DPLO: 0.82 )
Ranked among companies with meaningful Interest Coverage only.
DPLO' s Interest Coverage Range Over the Past 10 Years
Min: 0.82  Med: 5.55 Max: 15.18
Current: 0.82
0.82
15.18
Piotroski F-Score: 5
Altman Z-Score: 3.68
Beneish M-Score: -2.68
WACC vs ROIC
4.94%
-1.02%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 0.55
DPLO's Operating Margin % is ranked lower than
69% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. DPLO: 0.55 )
Ranked among companies with meaningful Operating Margin % only.
DPLO' s Operating Margin % Range Over the Past 10 Years
Min: 0.41  Med: 0.73 Max: 1.36
Current: 0.55
0.41
1.36
Net Margin % 0.04
DPLO's Net Margin % is ranked lower than
68% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. DPLO: 0.04 )
Ranked among companies with meaningful Net Margin % only.
DPLO' s Net Margin % Range Over the Past 10 Years
Min: -1.72  Med: 0.35 Max: 0.77
Current: 0.04
-1.72
0.77
ROE % 0.31
DPLO's ROE % is ranked lower than
64% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. DPLO: 0.31 )
Ranked among companies with meaningful ROE % only.
DPLO' s ROE % Range Over the Past 10 Years
Min: 0.31  Med: 6.32 Max: 10
Current: 0.31
0.31
10
ROA % 0.13
DPLO's ROA % is ranked lower than
62% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. DPLO: 0.13 )
Ranked among companies with meaningful ROA % only.
DPLO' s ROA % Range Over the Past 10 Years
Min: -14.87  Med: 1.31 Max: 3.7
Current: 0.13
-14.87
3.7
ROC (Joel Greenblatt) % 22.41
DPLO's ROC (Joel Greenblatt) % is ranked higher than
59% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. DPLO: 22.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DPLO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -91.68  Med: 17.17 Max: 59.73
Current: 22.41
-91.68
59.73
3-Year Revenue Growth Rate 4.30
DPLO's 3-Year Revenue Growth Rate is ranked lower than
54% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. DPLO: 4.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DPLO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.3  Med: 14.65 Max: 36
Current: 4.3
4.3
36
3-Year EBITDA Growth Rate 34.10
DPLO's 3-Year EBITDA Growth Rate is ranked higher than
87% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. DPLO: 34.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DPLO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 22.45 Max: 160.7
Current: 34.1
0
160.7
3-Year EPS without NRI Growth Rate 27.90
DPLO's 3-Year EPS without NRI Growth Rate is ranked higher than
76% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. DPLO: 27.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DPLO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 13.95 Max: 44.2
Current: 27.9
0
44.2
GuruFocus has detected 3 Warning Signs with Diplomat Pharmacy Inc DPLO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DPLO's 30-Y Financials

Financials (Next Earnings Date: 2019-02-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

DPLO Guru Trades in Q4 2017

Chris Davis 1,799,128 sh (+5.51%)
Steven Cohen 61,640 sh (-84.48%)
» More
Q1 2018

DPLO Guru Trades in Q1 2018

Steven Cohen 939,562 sh (+1424.27%)
Chris Davis 481,187 sh (-73.25%)
» More
Q2 2018

DPLO Guru Trades in Q2 2018

Joel Greenblatt 8,815 sh (New)
Wilbur Ross 6,965 sh (New)
Mariko Gordon 592,659 sh (New)
Chris Davis Sold Out
Steven Cohen Sold Out
» More
Q3 2018

DPLO Guru Trades in Q3 2018

Joel Greenblatt 79,394 sh (+800.67%)
Wilbur Ross 6,965 sh (unchged)
Mariko Gordon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:DPLO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:RDUS, BOM:532872, BOM:533573, SHSE:603367, NAS:IPXL, TSE:8129, NAS:PAHC, SHSE:600329, XKRX:003520, TSE:4569, SZSE:300630, BOM:540596, TSX:LEAF, SZSE:300401, FRA:DMP, NAS:PCRX, NAS:ENDP, NAS:MNTA, SZSE:002435, BOM:524494 » details
Traded in other countries:7DP.Germany,
Headquarter Location:USA
Diplomat Pharmacy Inc is a provider of pharmaceutical drugs in the United States. It generates its revenue through the sale of prescriptions drugs for serious diseases such as hepatitis and multiple sclerosis.

Diplomat Pharmacy Inc is active within United States' healthcare sector. It offers a range of services related to medical care, especially pharmacy solutions for chronic diseases such as hepatitis, multiple sclerosis, and other long-term conditions. Furthermore, it renders clinical services, drug-specific compliance, and persistency programs support, patient financial assistance and clinical and administrative support services to hospitals. The company derives most of its revenue through prescription drug sales in the United States.

Ratios

vs
industry
vs
history
PE Ratio 353.22
DPLO's PE Ratio is ranked lower than
98% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.77 vs. DPLO: 353.22 )
Ranked among companies with meaningful PE Ratio only.
DPLO' s PE Ratio Range Over the Past 10 Years
Min: 25.51  Med: 106.12 Max: 562.6
Current: 353.22
25.51
562.6
Forward PE Ratio 15.92
DPLO's Forward PE Ratio is ranked higher than
50% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.60 vs. DPLO: 15.92 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 353.22
DPLO's PE Ratio without NRI is ranked lower than
98% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.20 vs. DPLO: 353.22 )
Ranked among companies with meaningful PE Ratio without NRI only.
DPLO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 25.51  Med: 106.12 Max: 562.6
Current: 353.22
25.51
562.6
Price-to-Owner-Earnings 36.03
DPLO's Price-to-Owner-Earnings is ranked higher than
82% of the 324 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.95 vs. DPLO: 36.03 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DPLO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.34  Med: 21.25 Max: 62.43
Current: 36.03
12.34
62.43
PB Ratio 1.38
DPLO's PB Ratio is ranked higher than
66% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. DPLO: 1.38 )
Ranked among companies with meaningful PB Ratio only.
DPLO' s PB Ratio Range Over the Past 10 Years
Min: 1.36  Med: 2.51 Max: 9.4
Current: 1.38
1.36
9.4
PS Ratio 0.20
DPLO's PS Ratio is ranked higher than
97% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. DPLO: 0.20 )
Ranked among companies with meaningful PS Ratio only.
DPLO' s PS Ratio Range Over the Past 10 Years
Min: 0.19  Med: 0.38 Max: 1.06
Current: 0.2
0.19
1.06
Price-to-Free-Cash-Flow 18.34
DPLO's Price-to-Free-Cash-Flow is ranked higher than
88% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.84 vs. DPLO: 18.34 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DPLO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.75  Med: 23.75 Max: 230.8
Current: 18.34
9.75
230.8
Price-to-Operating-Cash-Flow 13.53
DPLO's Price-to-Operating-Cash-Flow is ranked higher than
85% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. DPLO: 13.53 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DPLO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.01  Med: 18.52 Max: 85.96
Current: 13.53
9.01
85.96
EV-to-EBIT 54.94
DPLO's EV-to-EBIT is ranked lower than
94% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. DPLO: 54.94 )
Ranked among companies with meaningful EV-to-EBIT only.
DPLO' s EV-to-EBIT Range Over the Past 10 Years
Min: 20.9  Med: 70.3 Max: 227.5
Current: 54.94
20.9
227.5
EV-to-EBITDA 13.84
DPLO's EV-to-EBITDA is ranked lower than
61% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. DPLO: 13.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
DPLO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.6  Med: 22 Max: 109
Current: 13.84
10.6
109
EV-to-Revenue 0.32
DPLO's EV-to-Revenue is ranked higher than
96% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. DPLO: 0.32 )
Ranked among companies with meaningful EV-to-Revenue only.
DPLO' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 0.5 Max: 1.3
Current: 0.32
0.2
1.3
Current Ratio 0.95
DPLO's Current Ratio is ranked lower than
89% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. DPLO: 0.95 )
Ranked among companies with meaningful Current Ratio only.
DPLO' s Current Ratio Range Over the Past 10 Years
Min: 0.82  Med: 1.22 Max: 2.09
Current: 0.95
0.82
2.09
Quick Ratio 0.66
DPLO's Quick Ratio is ranked lower than
89% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. DPLO: 0.66 )
Ranked among companies with meaningful Quick Ratio only.
DPLO' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 0.75 Max: 1.58
Current: 0.66
0.56
1.58
Days Inventory 14.13
DPLO's Days Inventory is ranked higher than
95% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. DPLO: 14.13 )
Ranked among companies with meaningful Days Inventory only.
DPLO' s Days Inventory Range Over the Past 10 Years
Min: 7.11  Med: 15.49 Max: 18.62
Current: 14.13
7.11
18.62
Days Sales Outstanding 22.24
DPLO's Days Sales Outstanding is ranked higher than
91% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. DPLO: 22.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
DPLO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.24  Med: 26.08 Max: 27.61
Current: 22.24
22.24
27.61
Days Payable 23.79
DPLO's Days Payable is ranked lower than
86% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. DPLO: 23.79 )
Ranked among companies with meaningful Days Payable only.
DPLO' s Days Payable Range Over the Past 10 Years
Min: 23.79  Med: 35.86 Max: 36.48
Current: 23.79
23.79
36.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.80
DPLO's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. DPLO: -12.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DPLO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.4  Med: -19.95 Max: -12.8
Current: -12.8
-25.4
-12.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.27
DPLO's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. DPLO: 1.27 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DPLO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.26  Med: 1.91 Max: 2.1
Current: 1.27
1.26
2.1
Price-to-Median-PS-Value 0.52
DPLO's Price-to-Median-PS-Value is ranked higher than
77% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. DPLO: 0.52 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DPLO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.51  Med: 1.06 Max: 2.44
Current: 0.52
0.51
2.44
Earnings Yield (Greenblatt) % 1.85
DPLO's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. DPLO: 1.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DPLO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 1.4 Max: 4.8
Current: 1.85
0.4
4.8

More Statistics

Revenue (TTM) (Mil) $5,286.97
EPS (TTM) $ 0.04
Beta0.46
Volatility56.68%
52-Week Range $13.31 - 28.74
Shares Outstanding (Mil)74.47

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 5,566 5,953 6,575
EBIT (Mil $) 150 153 167
EBITDA (Mil $) 169 172 187
EPS ($) 0.82 0.90 1.03
EPS without NRI ($) 0.82 0.90 1.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}